|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
|
Hypercholesterolemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PCSK9 mutant proteins associated with hypercholesterolemia (S127R and D374Y) are more potent in decreasing LDL uptake than is wild-type PCSK9.
|
18354137 |
2008 |
|
Hypercholesterolemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PCSK9 gain of function mutations cause hypercholesterolaemia by a reduction of LDL receptor levels, while PCSK9 loss of function variants are associated with a reduction of LDL-C values and a decreased risk of coronary heart disease.
|
18708425 |
2008 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
|
25248569 |
2014 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia.
|
25989132 |
2015 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia.
|
27195910 |
2017 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis.
|
28637178 |
2017 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors have emerged as the add-on therapy on top of statins and/or ezetimibe for the treatment of hypercholesterolemia and ASCVD prevention.
|
28879791 |
2017 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer.
|
29650402 |
2019 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
PCSK9, through promoting lysosomal degradation of hepatic low-density lipoprotein (LDL) receptor, can decrease the clearance of plasma LDLs, leading to hypercholesterolaemia and consequent atherosclerotic plaque formation.
|
31236571 |
2019 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
PCSK9 regulates LDL receptor degradation and plays key roles in hypercholesterolemia and related cardiovascular diseases.
|
31593224 |
2019 |
|
Hypercholesterolemia
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
A higher activity of PCSK9 leads to lower liver LDLR levels, resulting in a reduction in LDL-uptake from circulation, and thus in hypercholesterolemia and associated atherosclerosis.
|
23317404 |
2013 |
|
Hypercholesterolemia
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree.
|
14727179 |
2004 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
A promising approach to treat hypercholesterolemia is inactivating the secreted protein PCSK9, an antagonist of the LDL receptor.
|
29985478 |
2018 |
|
Hypercholesterolemia
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Activation of PCSK9 can thus decrease the expression of LDLR in the liver and inhibit LDL uptake, which leads to hypercholesterolaemia.
|
28549755 |
2019 |
|
Hypercholesterolemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Additionally, in the entire study group (n=401), PCSK9 R496W and D374Y mutation carriers had increased total cholesterol (p=0.021), triglycerides (p=0.0001), HDL cholesterol (p=0.028), and low-density lipoproteins (LDL) cholesterol (p=0.028) levels.
|
29724976 |
2018 |
|
Hypercholesterolemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
All known mutations in PCSK9 causing hypercholesterolemia produce an increase in the enzymatic activity of this protease.
|
18559913 |
2008 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Although not preferred over statins because of limited clinical trial evidence of cardiovascular event reductions, dosing convenience, and expense, PCSK9 monoclonal antibodies will have a prominent role to play in the treatment of hypercholesterolemia, especially in patients needing large LDL reductions, including patients with many types of FH.
|
26424774 |
2015 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Anti-PCSK9 agents have been approved for the treatment of hypercholesterolemia.
|
31227343 |
2019 |
|
Hypercholesterolemia
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
By comparing the number of patients with gain-of-function mutations in PCSK9 with the number of familial hypercholesterolemia heterozygotes among subjects with hypercholesterolemia, the prevalence of subjects with gain-of-function mutations in PCSK9 in Norway can be estimated to one in 15,000.
|
18266662 |
2008 |
|
Hypercholesterolemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
By comparing the number of patients with gain-of-function mutations in PCSK9 with the number of familial hypercholesterolemia heterozygotes among subjects with hypercholesterolemia, the prevalence of subjects with gain-of-function mutations in PCSK9 in Norway can be estimated to one in 15,000.
|
18266662 |
2008 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Circulating PCSK9 causes hypercholesterolemia by reducing LDL receptors in hepatocytes.
|
29451410 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia.
|
31292220 |
2019 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Compared with wild type, PCSK9-GOF pigs had elevated cholesterol, triglyceride, and blood pressure levels at 3 and 6 months.
|
29175268 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Consequently, the role of PCSK9 in modulating circulating LDL makes it a promising therapeutic target for treating hypercholesterolemia and coronary heart disease.
|
20172854 |
2010 |